Gonzalo Sepúlveda-Hermosilla 1, Matías Freire 2, Alejandro Blanco 1, Javier Cáceres 2, Rodrigo Lizana 2, Liliana Ramos 2, Rodrigo Assar Cuevas 2, Diego Ampuero 2, Osvaldo Aren 3, Sara Chernilo 4, María L Spencer 5, Giuliano Bernal 6, Jacqueline Flores 7,

"An orthogonal analysis was performed using a qPCR EML4-ALK fusion detection kit. ALK fusion prevalence is very

similar for Chile (3.67%, N=2142), Brazil (4.05%, N=1013) and Peru (4.59%,N=675). Whereas a comparison between

OFA and SofC assays showed similar sensitivity, OFA had significantly higher specificity and higher positive

predictive value, which opens new opportunities for a more specific determination of ALK gene rearrangements."

J Mol Diagn. 2021 Sep;23(9):1127-1137. 

Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi
Qingqing Ma 1, Dengming Ma 2, Mu Lin 1, Yadong Gong 1, Xiaojing Han 1, Yunhua Chen 1, Zhu Tang 1, Mubo Liu

Multigene mutation detection contributes to the rapid screening of patients with lung adenocarcinoma who respond to targeted therapy.

Biomed Res Int. 2021 May 28;2021:9939065. 

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report
Xiaomin Niu 1, Yingjia Sun 1, David Planchard 2, Luting Chiu 3, Jian Bai 3, Xinghao Ai 1, Shun Lu

"We demonstrate the case of 62-year-old female non-smoker with high PD-L1 expression and BRAF V600E mutated

NSCLC. The progression-free survival (PFS) of firstline combination of atezolizumab with platinum-based

chemotherapy and sequential

second-line treatment with BRAFi Vemurafenib are 20 and 5.5 months, respectively."

Front Oncol. 2021 Jun 10;11:634920. 

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC
Yukun Kuang, Peihang Xu, Jiyu Wang, Yifan Zheng, Xue Sun, Zimu Li, RunJing Gan, Huixia Li, Yubiao Guo, Fei Yao, Changbin Zhu, Zunfu Ke & Kejing Tang

Compared with NGS, RT-PCR appears to be a reliable method of detecting EML4-ALK fusion in patients with NSCLC.

Mol Diagn Ther. 2021 Jun 16. 

Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
"Tianan Guo1,2*, Yuchen Wu1,2*, Dan Huang2,3*, Yutong Jin4, Weiqi Sheng2,3, Sanjun Cai1,2, Xiaoyan Zhou2,3, Xiaoli Zhu2,3, Fangqi Liu1,2, Ye Xu1"

In KRAS-mutated CRC, exon 3 mutations predict the worst prognosis, while exon 4 mutations predict the best prognosis. Among KRAS exon 2 mutated patients, codon 13 mutations predict worse prognosis than codon 12 mutations. Mutations of different KRAS exons should be analyzed separately.

Journal of Cancer. 2021; 12(17): 5331-5337. 

High-Expression of Cytoplasmic Poly (A) Binding Protein 1 (PABPC1) as a Prognostic Biomarker for Early-Stage Esophageal Squamous Cell Carcinoma
Jiangtao Pu 1, Tao Zhang 1, Dengguo Zhang 1, Kaiming He 1, Yonghong Chen 2, Xingwang Sun 3, Wenbo Long

In this study, we discovered that PABPC1 is a prognostic biomarker and a therapeutic target for ESCC, particularly early-stage ESCC.

Cancer Manag Res. 2021 Jul 5;13:5361-5372.